Delaware Reminds Litigants Not to Wait to Disclose Infringement Theories Under the Doctrine of Equivalents
Federal Circuit Endorses the Doctrine of Equivalents Again for Lilly’s ALIMTA®: Different Amendment, Same Result
At 40 Years Old, the Orange Book Gets a Fresh Look as FDA Seeks Comments on Patent Listability
Feel Like DOE is Having a Rebirth in Life Science Cases? You’re Not Alone
Even If the Federal Circuit Could Award Attorney Fees for IPR Appeals, § 285 Does Not Permit It to Award Fees Incurred During the IPR
Update: Recent International Activity on IP in Response to COVID-19
New Treatments for COVID-19: Recent International Activity Relating to IP and Some Tools the US Already Has in Place
“Numerous Reasons” Support Finding Inequitable Conduct: Another Example of the Federal Circuit’s Current Approach to Inequitable Conduct
